Canada-based Alethia BioTheraputics has received $4.7m in venture capital funding which it will use to fund its antibody therapeutics program for cancer.
Canada-based Alethia BioTheraputics has received $4.7m in its series B round from a consortium including healthcare comapny Cellscript.
Alongside Cellscript, an existing shareholder in Alethia, in the round were venture capital firms AgeChem Venture Fund, BDC Venture Capital and GO Capital.
Alethia previously raised $9.2m in its series A round from AgeChem Venture Fund, BDC Venture Capital and GO Capital Fund and Epicentre Technologies in September 2010. This came two years after BDC Capital and Go Capital initially joined forces…
